



Summit Therapeutics plc
(‘Summit’ or the ‘Company’)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019

Oxford, UK, and Cambridge, MA, US, 25 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the fourth quarter and fiscal year ended 31 January 2019 on 27 March 2019.

Summit will host a conference call and webcast the same day to discuss its operational progress at 12:00 noon GMT / 8:00am EDT. Conference call and webcast information will be included in the full year results press release. A replay of the call will also be available through the Company's website, www.summitplc.com, shortly after its conclusion.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for *C. difficile* infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

Glyn Edwards / Richard Pye (UK office)
Michelle Avery (US office)

Tel: 44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Broker)

Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Tel: +44 (0)20 7496 3000

Bryan Garnier & Co Limited (Joint Broker)

Phil Walker / Dominic Wilson

Tel: +44 (0)20 7332 2500

MSL Group (US)

Jon Siegal

Tel: +1 781 684 6557
summit@mslgroup.com

Consilium Strategic Communications (UK)

Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /
Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-